SSA
SRPT icon

Schonfeld Strategic Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-67,500
Closed -$8.18M – 2187
2023
Q3 		$8.18M Buy
+67,500
New +$7.63M 0.06% 405
2021
Q1 		– Sell
-70,000
Closed -$11.9M – 2108
2020
Q4 		$11.9M Buy
+70,000
New +$10.4M 0.16% 172

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Schonfeld Strategic Advisors's SRPT Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 24,620 shares — an estimated $530K sold.

Schonfeld Strategic Advisors first reported a position in SRPT in Q2 2016 and held it in 32 quarters. The position peaked at $18.9M in Q4 2022. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 24,620 Sarepta Therapeutics shares in Q1 2026, an estimated $530K.
  • Schonfeld Strategic Advisors first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 32 quarters.
  • Schonfeld Strategic Advisors's Sarepta Therapeutics position peaked at $18.9M in Q4 2022.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.